tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Kevin Fischbeck, 29 are a SELL (13.55%), 119 are a BUY (55.61%), 66 are a HOLD (30.84%).
Analyst Kevin Fischbeck, currently employed at BAML, carries an average stock price target met ratio of 67.52% that have a potential upside of 25.3% achieved within 253 days.
Kevin Fischbeck’s has documented 404 price targets and ratings displayed on 33 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on HUM, Humana at 24-Jun-2026.
Analyst best performing recommendations are on CLOV (CLOVER HEALTH INVESTMENTS CORP).
The best stock recommendation documented was for HUM (HUMANA) at 6/24/2026. The price target of $380 was fulfilled within 2 days with a profit of $18.36 (5.08%) receiving and performance score of 25.38.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 03-Mar-2026
$105
$13.39 (14.62%)
$80
Buy Since 10-May-2021
$141
$49.39 (53.91%)
$72
Sell Since 11-Nov-2024
$81
$-10.61 (-11.58%)
$0.5
Buy Since 20-Oct-2023
$95
$3.39 (3.70%)
$13
Hold Since 15-Apr-2025
$55
$-36.61 (-39.96%)
$4
Which stock is Kevin Fischbeck is most bullish on?
Which stock is Kevin Fischbeck is most reserved on?
What Year was the first public recommendation made by Kevin Fischbeck?
